Hao Wu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Liquid Chromatography

Muscle Invasive Bladder Cancer

Acute Coronary Syndrome

Top Venues

Cancer medicine

Exploration (Beijing, China)

This page only lists publications with an associated author ORCID identifier.

Publications

Peng Xu, Wen Luo, Jingjing Hu, Xiaobin Ma, Qian Hao, Wentao Hui, Zhangjian Zhou, Shuai Lin, Meng Wang, Hao Wu, Zhi-Jun Dai, Huafeng Kang
Favorable outcome of neoadjuvant endocrine treatment than surgery-first in female HR-positive/HER2-negative breast cancer patients-A NCDB analysis (2010-2016). Cancer medicine 13 (11) (2024)
Maoxin Lv, Shihao Shang, Kepu Liu, Yuliang Wang, Peng Xu, Hao Song, Jie Zhang, Zelong Sun, Yuhao Yan, Zheng Zhu, Hao Wu, Hao Li
Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches. Pharmaceutics 16 (8) (2024)
Maoxin Lv, Shihao Shang, Kepu Liu, Yuliang Wang, Peng Xu, Hao Song, Jie Zhang, Zelong Sun, Yuhao Yan, Zheng Zhu, Hao Wu, Hao Li
Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches. Pharmaceutics 16 (8) (2024)
Peng Xu, Wen Luo, Jingjing Hu, Xiaobin Ma, Qian Hao, Wentao Hui, Zhangjian Zhou, Shuai Lin, Meng Wang, Hao Wu, Zhi-Jun Dai, Huafeng Kang
Favorable outcome of neoadjuvant endocrine treatment than surgery-first in female HR-positive/HER2-negative breast cancer patients-A NCDB analysis (2010-2016). Cancer medicine 13 (11) (2024)
Guoyin Li, Zewen Song, Yi Ru, Jing Zhang, Lianxiang Luo, Wei Yang, Hao Wu, Haibao Jin, Xuanwen Bao, Di Wei, Zhao Yan, Haijing Qu, Zheng Zhu, Xiangdong Xue, Gang Zhou
Small-molecule nanoprodrug with high drug loading and EGFR, PI3K/AKT dual-inhibiting properties for bladder cancer treatment. Exploration (Beijing, China) 3 (5) (2023)
Luyao Dai, Hanxiao Cui, Yuanhang Bao, Liqun Hu, Zhangjian Zhou, Meng Wang, Shuai Lin, Hao Wu, Huafeng Kang, Xiaobin Ma
The relationship between immediate postmastectomy reconstruction modalities and survival benefits in patients with triple negative breast cancer. Cancer medicine (2022)